Drug Type Small molecule drug |
Synonyms Evacetrapib (USAN), LY-2484595 |
Target |
Action inhibitors |
Mechanism CETP inhibitors(Cholesteryl ester transfer protein inhibitors) |
Therapeutic Areas |
Active Indication- |
Inactive Indication |
Originator Organization |
Active Organization- |
Inactive Organization |
Drug Highest PhaseDiscontinuedPhase 3 |
First Approval Date- |
Regulation- |
Molecular FormulaC31H36F6N6O2 |
InChIKeyIHIUGIVXARLYHP-YBXDKENTSA-N |
CAS Registry1186486-62-3 |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
D10121 | Evacetrapib | - |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Primary hypercholesterolemia | Phase 3 | Japan | 01 Nov 2014 | |
Hypercholesterolemia | Phase 3 | United States | 01 Oct 2014 | |
Hypercholesterolemia | Phase 3 | Puerto Rico | 01 Oct 2014 | |
Primary Hyperlipidemia | Phase 3 | United States | 01 Oct 2014 | |
Primary Hyperlipidemia | Phase 3 | Puerto Rico | 01 Oct 2014 | |
Vascular Diseases | Phase 3 | United States | 01 Oct 2012 | |
Vascular Diseases | Phase 3 | China | 01 Oct 2012 | |
Vascular Diseases | Phase 3 | Japan | 01 Oct 2012 | |
Vascular Diseases | Phase 3 | Argentina | 01 Oct 2012 | |
Vascular Diseases | Phase 3 | Australia | 01 Oct 2012 |
Phase 1 | - | 72 | Placebo | tkvfzrxhsz(nuawvoclry) = thmrtwbamj osbecrnvvg (dbvnazbprp, 7.5) View more | - | 07 Mar 2019 | |
Phase 1 | - | 8 | bravfycnkx(lodayrxglg) = eatoydinmg bpznmcgdcc (vutglegxox, lsxrpycofn - jwhotkefys) View more | - | 01 Mar 2019 | ||
Phase 1 | - | 95 | (Evacetrapib Reference (R)) | zfidgucikj(igdxkdimsq) = hrmpnbqnwf prxdcpspcc (xnrxbrecjm, 78) View more | - | 03 Dec 2018 | |
(Evacetrapib Test 1 (T1)) | zfidgucikj(igdxkdimsq) = jhaggtulga prxdcpspcc (xnrxbrecjm, 56) View more | ||||||
Phase 2 | 165 | Placebo+LY2484595 (100 mg LY2484595) | xdyievmbag(giypqwbiba) = xnfngtuard kljtguvntx (coklqfreep, 8.92) View more | - | 25 Oct 2018 | ||
Placebo+LY2484595 (500 mg LY2484595) | xdyievmbag(giypqwbiba) = tstjwedjwl kljtguvntx (coklqfreep, 9.16) View more | ||||||
Phase 1 | 32 | (Evacetrapib (Healthy)) | kuuainfzax(qluqfywsrw) = xzyplhcwzs vcjdgamcgv (tmxwtrsufa, 50) View more | - | 12 Oct 2018 | ||
(Evacetrapib (Hepatic, Mild)) | kuuainfzax(qluqfywsrw) = whhizfdrpv vcjdgamcgv (tmxwtrsufa, 84) View more | ||||||
Phase 1 | - | 40 | (Evacetrapib (Fasted)) | avftwnzcvw(dpgiqmngxd) = qbxmrctbci aegaoumlgp (marbcsevee, 73) View more | - | 12 Oct 2018 | |
High-fat Meal+Evacetrapib (Evacetrapib (Fed)) | avftwnzcvw(dpgiqmngxd) = ararmfwzqt aegaoumlgp (marbcsevee, 22) View more | ||||||
Phase 1 | - | 48 | (Reference (Fasted)) | wjkhepdnar(vamodtwqlk) = czictzupxj cjqlqizlzi (wxdwfbjviv, 40) View more | - | 10 Oct 2018 | |
(Test (Fasted)) | wjkhepdnar(vamodtwqlk) = tlgmsxtjwv cjqlqizlzi (wxdwfbjviv, 36) View more | ||||||
Phase 3 | 54 | (Evacetrapib) | vtcrnwxkiw(ixqsbplxde) = nuiijgtygk zzfbjivxsi (pfwztbomqt, 3.908) View more | - | 09 Oct 2018 | ||
Evacetrapib+Placebo (Placebo) | vtcrnwxkiw(ixqsbplxde) = kgadplcbce zzfbjivxsi (pfwztbomqt, 3.984) View more | ||||||
Phase 1 | - | 23 | (Ortho-Cyclen) | nyufkevzcv(onfxbtyzod) = aqkzhsnowj ztefniofak (cawvqovhut, 35) View more | - | 09 Oct 2018 | |
(Ortho-Cyclen + Evacetrapib) | nyufkevzcv(onfxbtyzod) = smmfpdplmv ztefniofak (cawvqovhut, 37) View more | ||||||
Phase 1 | 20 | (Evacetrapib (Participants With Renal Impairment)) | vobaxqfidu(zabcjqctzj) = sttldfcrei nalajmlrjx (nbabodemfi, 49) View more | - | 09 Oct 2018 | ||
(Evacetrapib (Healthy Participants)) | vobaxqfidu(zabcjqctzj) = zgrxxmxthw nalajmlrjx (nbabodemfi, 37) View more |